NeuroSense Therapeutics to Present Promising Phase 2b Data for ALS Treatment PrimeC at 77th Annual AAN Meeting

NeuroSense Therapeutics, a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, announced t...

April 07, 2025 | Monday | News
Keymed Biosciences' IL-4Rα Antibody Stapokibart Shows Promising Results in Phase III Trial for Seasonal Allergic Rhinitis

Keymed Biosciences Inc. announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its ...

April 07, 2025 | Monday | News
ABL Bio and GSK Forge Licensing Agreement to Develop Innovative Neurodegenerative Disease Treatments Using BBB Shuttle Platform

ABL Bio Inc. a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a wor...

April 07, 2025 | Monday | News
Rhythm Pharmaceuticals to Announce Topline Results from Phase 3 TRANSCEND Trial of Setmelanotide in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendoc...

April 07, 2025 | Monday | News
AstraZeneca’s Imfinzi (Durvalumab) Gains European Union Approval for Resectable Non-Small Cell Lung Cancer Treatment

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adult...

April 07, 2025 | Monday | News
AVITA Medical Launches Cohealyx™ in the U.S., Expanding Portfolio for Transformative Acute Wound Care

AVITA Medical, Inc., a leading therapeutic acute wound care company delivering transformative solutions, announced the U.S. commercial launch of Cohealyx&t...

April 07, 2025 | Monday | News
Amgen’s UPLIZNA Receives FDA Approval as First Treatment for IgG4-Related Disease, Cutting Flare Risk by 87%

Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo  UPLIZNA Shown to De...

April 04, 2025 | Friday | News
Novartis Receives FDA Accelerated Approval for Vanrafia® in Treatment of Primary IgA Nephropathy

Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective e...

April 03, 2025 | Thursday | News
Genentech Reports Phase III MUSETTE Trial Results for Ocrevus® Showing No Additional Benefit from Higher Dose in Relapsing MS

Genentech, a member of the Roche Group, announced  that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...

April 03, 2025 | Thursday | News
Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s Disease Treatment

Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oli...

April 03, 2025 | Thursday | News
Roche Reports Phase III MUSETTE Trial Results Showing No Additional Benefit from Higher Dose of OCREVUS® in Relapsing MS

Roche announced that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OC...

April 03, 2025 | Thursday | News
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from China’s NMPA for Melanoma Treatment

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...

April 02, 2025 | Wednesday | News
Castle Biosciences to Present Key Data on DecisionDx-Melanoma at EADO 2025 Congress

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the ...

April 02, 2025 | Wednesday | News
Inventiva Completes Patient Enrollment in Phase 3 NATiV3 Trial for MASH Treatment

Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecule dru...

April 02, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close